Free Trial
NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Price, News & Analysis

SAB Biotherapeutics logo
$2.57 -0.27 (-9.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.67 +0.10 (+3.89%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About SAB Biotherapeutics Stock (NASDAQ:SABS)

Key Stats

Today's Range
$2.57
$2.86
50-Day Range
$1.69
$2.84
52-Week Range
$1.00
$5.01
Volume
11,307 shs
Average Volume
69,359 shs
Market Capitalization
$23.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.25
Consensus Rating
Buy

Company Overview

SAB Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

SABS MarketRank™: 

SAB Biotherapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 399th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    SAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    SAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about SAB Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($3.69) to ($2.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of SAB Biotherapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of SAB Biotherapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    SAB Biotherapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about SAB Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.28% of the float of SAB Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SAB Biotherapeutics has recently decreased by 36.98%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    SAB Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    SAB Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.28% of the float of SAB Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in SAB Biotherapeutics has recently decreased by 36.98%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for SAB Biotherapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.77% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.82% of the stock of SAB Biotherapeutics is held by institutions.

  • Read more about SAB Biotherapeutics' insider trading history.
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SABS Stock News Headlines

SABS - SAB Biotherapeutics Inc Sustainability | Morningstar
When your faith is put to the test, what will you do?
Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 trillion “birthright” tied to America’s untouched wealth. He says the Book of Genesis predicted this moment… and those who act now could be first in line to benefit. The full presentation is now live.
SAB Biotherapeutics Inc (SABS) - Investing.com
SABS - SAB Biotherapeutics Inc Chart - Morningstar
Craig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)
See More Headlines

SABS Stock Analysis - Frequently Asked Questions

SAB Biotherapeutics' stock was trading at $3.79 at the beginning of 2025. Since then, SABS shares have decreased by 32.2% and is now trading at $2.57.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) released its quarterly earnings results on Friday, May, 9th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.44.

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include ChargePoint (CHPT), PayPal (PYPL), Coinbase Global (COIN), Tesla (TSLA), Confluent (CFLT), CrowdStrike (CRWD) and Ford Motor (F).

Company Calendar

Last Earnings
5/09/2025
Today
7/20/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SABS
CIK
1833214
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+415.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.10 million
Net Margins
N/A
Pretax Margin
-9,067.72%
Return on Equity
-105.14%
Return on Assets
-69.24%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
1.69
Quick Ratio
1.69

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.81 per share
Price / Book
0.91

Miscellaneous

Outstanding Shares
9,289,000
Free Float
6,709,000
Market Cap
$23.87 million
Optionable
Not Optionable
Beta
0.52
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SABS) was last updated on 7/20/2025 by MarketBeat.com Staff
From Our Partners